The above button links to Coinbase. Yahoo Finance is not a broker-dealer or investment adviser and does not offer securities or cryptocurrencies for sale or facilitate trading. Coinbase pays us for ...

Builds on recent FDA approval (May 29, 2026) of Afrezza for use in children and adolescents aged 6 and older living with type 1 and type 2 ...

Credit: MannKind. Backed by phase 3 INHALE-1 data, the expanded indication provides a noninvasive, needle-free mealtime insulin alternative for children and adolescents. Afrezza Inhalation Powder is ...

SACRAMENTO, Calif. — There’s a form of insulin that’s changing the lives of diabetics who use it, but doctors and patients alike say it doesn’t have widespread name recognition. It’s called Afrezza.

ORLANDO, Fla. — The inhaled insulin Afrezza combined with a long-acting basal analog offers a non-inferior insulin treatment option for people with type 1 diabetes, new phase 4 data suggest. Afrezza ...

MannKind Corporation announced that it will present data from five studies on inhaled insulin at the 18th International Conference on Advanced Technologies and Treatments for Diabetes in Amsterdam, ...

MannKind Corporation (Nasdaq: MNKD), a company focused on the development and commercialization of inhaled therapeutic products and devices for patients with endocrine and orphan lung diseases, today ...

The updated labeling provides a new conversion chart for starting dosages when switching patients from subcutaneous mealtime insulin to Afrezza. The Food and Administration (FDA) has approved updated ...

Most of the 38 million people living with diabetes in the U.S. use daily injections or insulin pumps to keep glucose at safe levels — but new research suggests that a third option could be just as ...

Enables dosing at the start of a meal, offering flexibility for children and adolescents as they manage school, sports, meals, and snacks throughout the day Approval advances pediatric diabetes care ...